

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **PROFIT WARNING**

This announcement is made by Lee's Pharmaceutical Holdings Limited (the "**Company**"), together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the Group's unaudited financial information currently available, the Group is expected to record an unaudited net profit attributable to the Shareholders of between HK\$12 million and HK\$17 million for the six months ended 30 June 2023 as compared with approximately HK\$28 million recorded for the six months ended 30 June 2022.

Based on information currently available, the Board is of the view that, despite implementing cost-saving measures, the decrease in the profit attributable to the Shareholders of the Company for the six months ended 30 June 2023 is mainly attributable to, among other things, (i) decreased sales revenue due to the price cut of certain products in exchange for being included in the national reimbursement scheme; (ii) decreased gross profit margin for the product under national volume based procurement program; and (iii) decreased gross profit margin as a result of the decrease in the sales revenue due to the depreciation of the Renminbi in the first half of 2023.

The Company is still in the process of finalising the results for the six months ended 30 June 2023. The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023, which have not been confirmed, reviewed or audited by the auditors of the Company.

\* *For identification purpose only*

The interim results announcement of the Company for the six months ended 30 June 2023 is expected to be published by the end of August 2023 in full compliance with the requirements under Listing Rules.

**Shareholders and potential investors are advised to exercise cautions when dealing in the shares of the Company.**

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 21 August 2023

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors, Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*